A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Traztuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer

Trial Profile

A Phase 1b, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Traztuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2015

At a glance

  • Drugs Trastuzumab (Primary) ; Carboplatin; Docetaxel
  • Indications Solid tumours
  • Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Oct 2011 Planned end date changed from 1 Feb 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
    • 05 Oct 2011 Planned end date 1 Feb 2013 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top